抗凝血酶-Ⅲ在易栓症的应用
|
摘要
易栓症已由一种罕见的遗传性疾病转变为多发病。随着临床相关易栓症筛查的广泛开展,AT-Ⅲ在易栓症中的研究也越来越深入和系统。
Thrombotic disease has changed from a rare hereditary disease to a frequent disease.With the development of clinical screening for thrombotic disorders,the research of AT-Ⅲ in thrombotic disorders is more and more thorough and systematic.
Thrombotic disease has changed from a rare hereditary disease to a frequent disease.With the development of clinical screening for thrombotic disorders,the research of AT-Ⅲ in thrombotic disorders is more and more thorough and systematic.
引文
[1]王鸿利,王学峰.血栓病临床新技术[M].北京:人民军医出版社,2003.
[2]孟涛,王建春.观察肺炎支原体肺炎患儿血浆内皮素和AT-Ⅲ的变化[J].实用医技杂志,2006,13(1):39-40.
[3]傅启华,王鸿利.遗传性抗凝血酶缺乏症研究进展[J].国外医学(输血及血液学分册),2003,26(2):114-116.
[4]Mammen EF.Antithrombin:its physiological importance and rolo in DIC[J].Semin Thromb Hermost,1998,24(1):19-25.
[5]王学峰,王鸿利.血栓与止血的检测与应用[M].上海:上海世界图书出版公司,2002.
[6]董存岩,周志芳.肝病患者血浆AT-Ⅲ活性检测及意义[J].实用预防医学,2004,11(2):264-265.
[7]尹栩芳,沈霞.冠心病患者血浆抗凝血酶Ⅲ活性和纤维蛋白原水平的临床价值[J].现代检验医学杂志,2014,29(3):141-143.
[8]金元玖,李正信,苗秀兰,等.不同临床类型冠心病患者抗凝血酶和纤溶系统的变化[J].中国医师杂志,2005,7(3):416-417.
[9]戴西艳,董明驹.血浆AT-Ⅲ活性测定在治疗AMI中的临床价值[J].中外健康文摘,2012,9(3):30-32.
[10]闫吉,王雅姝.动态监测抗凝血酶Ⅲ和D-二聚体在急性心肌梗死诊疗中的应用[J].中国使用诊断学,2015,19(1):45-47.
[11]张淑敏.抗凝血酶Ⅲ、D-二聚体、血小板聚集和纤维蛋白原测定与急性脑梗死的相关性[J].检验医学与临床,2011,08(4):453-454.
[12]Soare AM,Popa C.Deficiencies of proteins C,S and antithrombin and factor V Leiden and the risk of ischemic strokes[J].J Med Life,2010,3(3):235-238.
[13]韩玉霞,陈宝荣,高寒,等.抗凝血酶Ⅲ在急性脑梗死诊断及预测中的应用[J].中国实用神经疾病杂志,2007,10(6):30-31.
[14]覃乃辉,周达利,秦立,等.脑梗死患者血D-二聚体、超敏C反应蛋白及抗凝血酶Ⅲ的检测及意义[J].海南医学院学报,2014,20(1):50-53.
[15]白春梅,潘家绮,范连凯.静脉血栓患者抗凝蛋白缺陷研究[J].中华内科杂志,2000,39(11):746-748.
[16]Ho CH,Chau WK,Hsu HC,et al.Causes of venous thrombosis in fihy Chinese patients[J].Am J Hematol,2000,63(2):74-78.
[17]Franeo RF,Reitsma PH.Genetic risk factors of venous thrombosis[J].Hum Genet,2001,109(4):369-384.
[18]Vossen CY,Conard J,Fontcuberta J,et al.VTEvenous thrombotic event in cal Tiers of a familial thrombophilic defec L The European Prospective Cohort on Thrombophil ia(EPCOT)[J].J Thromb Haemost,2005,3(3):459-464.
[19]顾怡,傅启华.抗凝血酶研究进展[J].血栓与止血学,2011,17(1):36-38.
[20]Zhu T,Ding Q,Bai X,et al.Normal ranges and genetic variants of antithrombin,protein C and protein S in the general Chinese population.Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group[J].Haematologica,2011,96(7):1033-1040.
[21]Sagripanti A,Barsotti G.Hypercoagulability,intraglomerular coagulation,and thromboembolism in nephrotic syndrome[J].Nephron,1995,70(3):271-281.
[22]熊丽丽,魏文宁.抗凝血酶活性检测在弥漫性血管内凝血中的意义[J].血栓与止血学,2006,12(2):61-63.
[23]肖辉,薛冰蓉,张亚梅,等.几种新生儿疾病患儿DIC过筛试验各指标变化的研究[J].医学信息,2013,26(27):142-143.
[24]许燕京,朱然,孙旖旎,等.抗凝血酶Ⅲ对脓毒症DIC的早期诊断价值:附445例患者的回顾性分析[J].中华危病重急救医学,2017,29(2):127-132.
[25]Braekkan SK,Mathiesen EB,Njlstad I,et al.Hematocrit and risk of venous thromboembolism in a general population.The Tromso study[J].Haematologica,2010,95(2):270-275.
[26]Corral J,Hernandez-Espinosa D,Soria JM,et al.Antithrombin Cambridge II(A384S):an underestimated genetic risk factor for venous thrombosis[J].Blood,2007,109(10):4258-4263.
[27]Lentz SR.Mechanisms of homocysteine-induced atherothrombosis[J].J Thromb Haemost,2005,3(8):1646-1654.
[2]孟涛,王建春.观察肺炎支原体肺炎患儿血浆内皮素和AT-Ⅲ的变化[J].实用医技杂志,2006,13(1):39-40.
[3]傅启华,王鸿利.遗传性抗凝血酶缺乏症研究进展[J].国外医学(输血及血液学分册),2003,26(2):114-116.
[4]Mammen EF.Antithrombin:its physiological importance and rolo in DIC[J].Semin Thromb Hermost,1998,24(1):19-25.
[5]王学峰,王鸿利.血栓与止血的检测与应用[M].上海:上海世界图书出版公司,2002.
[6]董存岩,周志芳.肝病患者血浆AT-Ⅲ活性检测及意义[J].实用预防医学,2004,11(2):264-265.
[7]尹栩芳,沈霞.冠心病患者血浆抗凝血酶Ⅲ活性和纤维蛋白原水平的临床价值[J].现代检验医学杂志,2014,29(3):141-143.
[8]金元玖,李正信,苗秀兰,等.不同临床类型冠心病患者抗凝血酶和纤溶系统的变化[J].中国医师杂志,2005,7(3):416-417.
[9]戴西艳,董明驹.血浆AT-Ⅲ活性测定在治疗AMI中的临床价值[J].中外健康文摘,2012,9(3):30-32.
[10]闫吉,王雅姝.动态监测抗凝血酶Ⅲ和D-二聚体在急性心肌梗死诊疗中的应用[J].中国使用诊断学,2015,19(1):45-47.
[11]张淑敏.抗凝血酶Ⅲ、D-二聚体、血小板聚集和纤维蛋白原测定与急性脑梗死的相关性[J].检验医学与临床,2011,08(4):453-454.
[12]Soare AM,Popa C.Deficiencies of proteins C,S and antithrombin and factor V Leiden and the risk of ischemic strokes[J].J Med Life,2010,3(3):235-238.
[13]韩玉霞,陈宝荣,高寒,等.抗凝血酶Ⅲ在急性脑梗死诊断及预测中的应用[J].中国实用神经疾病杂志,2007,10(6):30-31.
[14]覃乃辉,周达利,秦立,等.脑梗死患者血D-二聚体、超敏C反应蛋白及抗凝血酶Ⅲ的检测及意义[J].海南医学院学报,2014,20(1):50-53.
[15]白春梅,潘家绮,范连凯.静脉血栓患者抗凝蛋白缺陷研究[J].中华内科杂志,2000,39(11):746-748.
[16]Ho CH,Chau WK,Hsu HC,et al.Causes of venous thrombosis in fihy Chinese patients[J].Am J Hematol,2000,63(2):74-78.
[17]Franeo RF,Reitsma PH.Genetic risk factors of venous thrombosis[J].Hum Genet,2001,109(4):369-384.
[18]Vossen CY,Conard J,Fontcuberta J,et al.VTEvenous thrombotic event in cal Tiers of a familial thrombophilic defec L The European Prospective Cohort on Thrombophil ia(EPCOT)[J].J Thromb Haemost,2005,3(3):459-464.
[19]顾怡,傅启华.抗凝血酶研究进展[J].血栓与止血学,2011,17(1):36-38.
[20]Zhu T,Ding Q,Bai X,et al.Normal ranges and genetic variants of antithrombin,protein C and protein S in the general Chinese population.Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group[J].Haematologica,2011,96(7):1033-1040.
[21]Sagripanti A,Barsotti G.Hypercoagulability,intraglomerular coagulation,and thromboembolism in nephrotic syndrome[J].Nephron,1995,70(3):271-281.
[22]熊丽丽,魏文宁.抗凝血酶活性检测在弥漫性血管内凝血中的意义[J].血栓与止血学,2006,12(2):61-63.
[23]肖辉,薛冰蓉,张亚梅,等.几种新生儿疾病患儿DIC过筛试验各指标变化的研究[J].医学信息,2013,26(27):142-143.
[24]许燕京,朱然,孙旖旎,等.抗凝血酶Ⅲ对脓毒症DIC的早期诊断价值:附445例患者的回顾性分析[J].中华危病重急救医学,2017,29(2):127-132.
[25]Braekkan SK,Mathiesen EB,Njlstad I,et al.Hematocrit and risk of venous thromboembolism in a general population.The Tromso study[J].Haematologica,2010,95(2):270-275.
[26]Corral J,Hernandez-Espinosa D,Soria JM,et al.Antithrombin Cambridge II(A384S):an underestimated genetic risk factor for venous thrombosis[J].Blood,2007,109(10):4258-4263.
[27]Lentz SR.Mechanisms of homocysteine-induced atherothrombosis[J].J Thromb Haemost,2005,3(8):1646-1654.